Valuation: Viyash Scientific Limited

Market Cap 95.37B 1B 900M 827M 750M 1.4B 1.43B 9.87B 3.96B 50.17B 3.77B 3.69B 158B P/E 2027 *
31.2x
P/E 2028 * 17.9x
Enterprise Value 95.37B 1B 900M 827M 750M 1.4B 1.43B 9.87B 3.96B 50.17B 3.77B 3.69B 158B EV / Sales 2027 *
2.45x
EV / Sales 2028 * 2.15x
Free-Float
44.4%
Yield 2027 *
-
Yield 2028 * -
1 day-2.82%
1 week+7.40%
Current month-7.36%
1 month-7.36%
3 months-13.26%
6 months+7.03%
Current year+4.97%
1 week 202.45
Extreme 202.45
232.7
1 month 197
Extreme 197
250.95
Current year 178.4
Extreme 178.4
297.9
1 year 178.4
Extreme 178.4
297.9
3 years 91.85
Extreme 91.85
297.9
5 years 61.8
Extreme 61.8
297.9
10 years 42.45
Extreme 42.45
336.4
Manager TitleAgeSince
Chief Executive Officer 62 2025-12-15
Director of Finance/CFO - 2025-12-31
Chief Tech/Sci/R&D Officer - 2026-02-04
Director TitleAgeSince
Chairman 78 2025-08-24
Director/Board Member 67 2020-08-24
Director/Board Member 57 2022-04-10
Change 5-day change 1-year change 3-year change Capi.($)
-2.82%+7.40%+2.41%+120.84% 1B
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +1.27%+6.05%+42.17%+86.91% 426.29B
Weighted average by Cap. +1.19%+6.60%+50.87%+98.32%

Financials

2027 *2028 *
Net sales 38.99B 411M 368M 338M 307M 573M 584M 4.03B 1.62B 20.51B 1.54B 1.51B 64.69B 44.28B 466M 418M 384M 348M 651M 663M 4.58B 1.84B 23.29B 1.75B 1.71B 73.46B
Net income 3.44B 36.21M 32.43M 29.83M 27.03M 50.53M 51.47M 356M 143M 1.81B 136M 133M 5.7B 5.65B 59.46M 53.25M 48.98M 44.38M 82.96M 84.51M 584M 234M 2.97B 223M 218M 9.37B
Net Debt - -
Projected Income Statement - Annual - Viyash Scientific Limited
Logo Viyash Scientific Limited
Viyash Scientific Limited, formerly SeQuent Scientific Limited, is an India-based integrated pharmaceutical company with a global footprint, operating in the domains of animal health (active pharmaceutical ingredients (APIs), and finished dosage formulations) and analytical services. The Company has eight manufacturing facilities, based in India, Turkey, Brazil, Spain and Germany. It is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It specializes in analytical and bioanalytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It offers analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer-developed methods or in-house method development.
Employees
2,900
Date Price Change Volume
26-10-30 ₹218.50 -2.82% 82,933
26-10-29 ₹224.85 -1.42% 161,547
26-10-28 ₹228.10 +6.07% 173,487
26-10-27 ₹215.05 +3.64% 90,333
26-10-26 ₹207.50 +1.99% 1,243,232
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Viyash Scientific Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
218.50INR
Average target price
326.00INR
Spread / Average Target
+49.20%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Viyash Scientific Limited
  1. Stock Market
  2. Stocks
  3. VIYASH Stock